
    
      Participants are given a regimen containing TDF 300mg and FTC 200mg fixed-dose combination
      tablet (TDF/FTC) once daily, and atazanavir, one 300mg tablet and one 100 mg ritonavir given
      once daily,for 28 days.
    
  